---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-020207"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2022-08-02T23:59:59+00:00"
generated_at: "2026-06-24T06:03:26.336302+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Arcutis gets FDA approval for ZORYVE (roflumilast) cream 0.3% for plaque psoriasis; draws $125M in debt

## Summary
- FDA approved ZORYVE (roflumilast) cream 0.3% for plaque psoriasis, including intertriginous areas, in patients 12+.
- First and only topical PDE4 inhibitor approved for plaque psoriasis; once-daily, steroid-free, no duration limit.
- Commencing $125M drawdown of Tranche B term loans from SLR Investment Corp. to fund launch and pipeline.
- Product expected to be available via wholesalers and dermatology pharmacies by mid-August 2022.
- DERMIS-1/2 Phase 3 trials: 42% and 37% IGA success at Week 8 (P<0.0001); itch reduction as early as Week 2.

## SEC filing metadata
- accession: 0001628280-22-020207
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2022-08-02T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000162828022020207/0001628280-22-020207-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000162828022020207/arqt-20220729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-020207
- JSON: https://secwatch.observer/filing/0001628280-22-020207.json
- Plain text: https://secwatch.observer/filing/0001628280-22-020207.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.